DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate. / Contenuti a solo scopo informativo e didattico, non costituiscono consulenza finanziaria né offerta o sollecitazione al pubblico risparmio ai sensi delle normative CONSOB e SEC. Le azioni biotech e le small/mid cap sono strumenti altamente speculativi e volatili e possono comportare la perdita parziale o totale del capitale investito. Si raccomanda di effettuare sempre le proprie ricerche e, se necessario, di rivolgersi a un consulente abilitato.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
⚠️ IMPORTANT NOTICE / AVVISO IMPORTANTE:
This document is a company analysis and financial summary compiled from publicly available sources (SEC filings, press releases, clinical publications). It is NOT investment advice, NOT a recommendation to buy or sell, and does NOT constitute a solicitation. The author is NOT a licensed financial advisor. Always conduct your own due diligence and consult qualified professionals before making any financial decisions.
Questo documento è un analisi aziendale e riepilogo finanziario compilato da fonti pubbliche (SEC filing, comunicati stampa, pubblicazioni cliniche). NON è un consiglio di investimento, NON è una raccomandazione. L'autore NON è un consulente finanziario autorizzato. Effettua sempre la tua due diligence.
This document is a company analysis and financial summary compiled from publicly available sources (SEC filings, press releases, clinical publications). It is NOT investment advice, NOT a recommendation to buy or sell, and does NOT constitute a solicitation. The author is NOT a licensed financial advisor. Always conduct your own due diligence and consult qualified professionals before making any financial decisions.
Questo documento è un analisi aziendale e riepilogo finanziario compilato da fonti pubbliche (SEC filing, comunicati stampa, pubblicazioni cliniche). NON è un consiglio di investimento, NON è una raccomandazione. L'autore NON è un consulente finanziario autorizzato. Effettua sempre la tua due diligence.
? Amarin Corporation (AMRN)
Company Analysis & Financial Summary — 10 Years of Vascepa: REDUCE-IT Success to Generic Competition
? VASCEPA STORY 2015-2025 ✓ REDUCE-IT GAME-CHANGER (2018) ⚠️ GENERIC COMPETITION 2020-2021
NASDAQ: AMRN | Current Price: ~$16.70 | Market Cap: ~$327M | 52-Week: $14.07 - $20.85 | Nov 2025
? Contents
1. Company Overview
Amarin Corporation plc is an Irish-incorporated biopharmaceutical company with headquarters in Bridgewater, New Jersey. The company's flagship product is Vascepa® (icosapent ethyl), a prescription omega-3 formulation indicated for reducing cardiovascular risk.
Amarin's remarkable story spans from near-bankruptcy in 2015 to $607M peak revenue (2020), then to steep decline due to generic competition beginning in 2020-2021. This is the definitive chronicle of that journey — backed by SEC filings and official press releases.
Key Timeline Facts:
- Founded: 1991 (originally Lorus Therapeutics)
- Vascepa FDA approved: July 2012 (monotherapy indication)
- REDUCE-IT results presented: November 10, 2018 (AHA Conference)
- CV indication approved: December 17, 2019 (FDA Accelerated Approval)
- Peak revenue: $607M (2020)
- Generic launch begins: November 2020 (Hikma); Q1-Q2 2021 (multiple generics)
- Current status (Nov 2025): Licensing revenue model; path to FCF positive 2026
2. 10-Year Timeline (2015-2025) — Verified Facts
2015-2017: Crisis Years
2015
Vascepa was commercially failing despite FDA approval. The drug, approved in July 2012 for high triglycerides monotherapy only, had minimal market adoption. Cardiologists weren't prescribing it, insurance companies blocked coverage, and the company was burning cash. Amarin faced potential bankruptcy.
- Problem: Narrow indication, small market, expensive
- Competition: OTC fish oils, generic statins
- Stock: Near all-time lows
2016-2017
REDUCE-IT trial in progress — company's survival dependent on results. Amarin had invested everything into REDUCE-IT, a massive 8,000+ patient cardiovascular outcomes trial. If it failed, the company would likely collapse.
2018: Turning Point
November 10, 2018
? REDUCE-IT Trial Results Presented at American Heart Association Conference
Results demonstrated icosapent ethyl (Vascepa) at 4g daily achieved 25% relative risk reduction in major adverse cardiovascular events (MACE):
- Primary endpoint: 17.2% MACE in Vascepa arm vs. 22% placebo (HR 0.75, p<0.0001)
- Number Needed to Treat (NNT): 21 patients treated = 1 event prevented
- Study population: 8,179 patients with elevated triglycerides on statin therapy
- Published: New England Journal of Medicine, November 2018
- No excess safety signals
Market impact: Stock soared. Wall Street now saw Vascepa as potentially multi-billion-dollar drug.
2019: FDA Approval for Cardiovascular Indication
December 17, 2019
✅ FDA Grants Accelerated Approval
FDA approved Vascepa for "reduction of cardiovascular risk in statin-treated patients with elevated triglyceride levels (135-499 mg/dL) and established CVD or diabetes."
- Massive market expansion (millions of statin-treated patients eligible)
- Insurance coverage began improving (though with restrictions)
- Stock: +30% on approval day
2020: Peak Year
2020
? Vascepa Becomes Best-Seller
| Metric | 2020 Actual (SEC 10-K) |
|---|---|
| Vascepa Product Revenue | $607.0M |
| Total Revenue | $609.7M |
| Stock Price Peak | ~$24/share |
- Strong uptake across US market
- Insurance coverage improving
- Cardiologist adoption accelerating
2021: Beginning of the End
2021
⚠️ Revenue declining — generics looming
| Metric | 2021 Actual (SEC 10-K) |
|---|---|
| Vascepa Product Revenue | $580.3M |
| Total Revenue | $583.8M |
| YoY Change vs 2020 | -4.5% decline |
| Stock Price (May 2021) | Peak: ~$28-29/share |
Why decline? Generic competition began in November 2020 (Hikma launched after winning patent litigation in March 2020). Market started shifting to cheaper alternatives.
2020-2021: Generic Launches Begin
November 2020
? First Generic Icosapent Ethyl Launches
Hikma launched generic icosapent ethyl after winning patent litigation (March 2020 court decision). This was the first competitive threat to Vascepa's market dominance.
Q1-Q2 2021
Multiple additional generics enter market
By mid-2021, at least 3-4 generic competitors had launched or were launching. Insurance companies rapidly shifted to cheaper alternatives.
- Amarin's market share in icosapent ethyl dropped from ~95% to ~50-60% by end of 2021
- Generic pricing: 40-50% lower than Vascepa brand
2022: Revenue Collapse
2022
Vascepa sales collapse under generic pressure
| Period | Value |
|---|---|
| Full Year 2022 Total Revenue | $92.0M |
| YoY Change vs 2021 | -84.2% |
| Stock Price (May 2022) | $2.71 (down 91% from 2021 peak) |
Company announced major restructuring: 40% workforce reduction, $100M cost cuts.
2024-2025: Licensing Revenue Model Emerges
H2 2025 (Jan-Jun)
Latest Financial Results (Per SEC 10-Q)
| Metric (H2 2025) | Value | H2 2024 | Change |
|---|---|---|---|
| Product Revenue | $93.2M | $83.8M | +11.2% |
| Licensing & Royalties | $52.2M | $0.9M | +5,689% |
| Total Revenue | $145.4M | $84.7M | +71.6% |
| Operating Loss | -$16.2M | -$50.1M | -67.7% (improving) |
| Cash + Investments | $286.6M | $305.7M | Stable |
Positive signs: Licensing revenue explosion (+5,689% YoY); Operating loss improving 67.7%; SG&A cut 46.6%. Company on path to positive cash flow in 2026.
Headwinds: Licensing includes one-time upfront payments; core product growth only +11.2% organic.
3. Vascepa: The Science
What is Vascepa?
Vascepa (icosapent ethyl) is a pharmaceutical-grade, highly concentrated omega-3 formulation containing eicosapentaenoic acid (EPA). It is NOT the same as over-the-counter fish oil.
Mechanism (From REDUCE-IT & Clinical Data)
| Mechanism | Effect |
|---|---|
| ↓ Triglycerides | Reduces plasma TG by 25-30% |
| ↓ Small dense LDL | Reduces atherogenic LDL particles |
| ↑ HDL | Modest HDL increase |
| Anti-inflammatory | Reduces CRP, IL-6, systemic inflammation |
| Plaque stabilization | Stabilizes existing atherosclerotic lesions |
4. REDUCE-IT Trial: Results & Clinical Impact
Trial Design (Published NEJM November 2018)
| Parameter | Detail |
|---|---|
| Trial Name | REDUCE-IT (Reduction of Cardiovascular Events with Icosapent Ethyl) |
| N | 8,179 patients randomized |
| Population | Statin-treated patients with TG 135-499 mg/dL, LDL 41-100 mg/dL (or <40 with established CVD) |
| Treatment | Icosapent ethyl 4g daily vs. placebo (both on statin) |
| Primary Endpoint | MACE: cardiovascular death, MI, stroke, coronary revascularization, unstable angina |
| Follow-up | Median 5 years (4.8 years actual) |
✅ Primary Results
- MACE incidence (IPE): 17.2%
- MACE incidence (Placebo): 22%
- Relative Risk Reduction: 25% (Hazard Ratio 0.75; 95% CI 0.68-0.83; p<0.0001)
- Number Needed to Treat (NNT): 21 patients treated to prevent 1 MACE event
- Absolute Risk Reduction: ~4.8 percentage points
Secondary Endpoints
- CV death/MI/stroke: 15.3% (IPE) vs. 21.2% (placebo; p<0.0001)
- Coronary revascularization: 11.4% (IPE) vs. 16.7% (placebo; NNT=24)
- Stroke: 2.6% (IPE) vs. 3.8% (placebo; p=0.009)
- Atrial fibrillation: 3.5% (IPE) vs. 2.2% (placebo) — small increase noted
- All-cause mortality: 7.5% (IPE) vs. 8.4% (placebo; not significant)
Why REDUCE-IT Mattered: First study proving that triglyceride reduction alone (beyond statin) prevents cardiovascular events in real patients. This changed cardiology guidelines and made Vascepa clinically relevant for millions of statin-treated patients.
5. Financial Analysis (Verified SEC Data)
5.1 Revenue Trajectory (SEC Filings Verified)
| Year | Vascepa Revenue ($M) | Total Revenue ($M) | YoY Change |
|---|---|---|---|
| 2019 | $428.8 | $430.5 | — |
| 2020 (Peak Year) | $607.0 | $609.7 | +41.6% |
| 2021 | $580.3 | $583.8 | -4.5% |
| 2022 | $89.5 | $92.0 | -84.6% |
| H2 2025 (6 mo) | $93.2 | $145.4 | New model: licensing |
5.2 H2 2025 Income Statement (SEC 10-Q Verified)
| Line Item ($M) | H2 2025 (6 months) | H2 2024 (6 months) | YoY Change |
|---|---|---|---|
| Product Revenue | 93.2 | 83.8 | +11.2% |
| Licensing & Royalties | 52.2 | 0.9 | +5,689% ? |
| Total Revenue | 145.4 | 84.7 | +71.6% |
| COGS | 55.0 | 52.0 | +5.8% |
| Gross Margin | 90.4 (62.2%) | 32.7 (38.6%) | +176% |
| SG&A | 39.4 | 73.8 | -46.6% |
| R&D | 8.4 | 9.0 | -6.7% |
| Restructuring Charges | 18.8 | — | — |
| Operating Loss | -16.2 | -50.1 | -67.7% (improving!) |
| Net Loss | -15.1 | -50.2 | -69.9% |
? Licensing Revenue EXPLODING (+5,689% YoY)
- H2 2025 Licensing Revenue: $52.2M (vs. $0.9M H2 2024)
- Source: Recordati partnership (European Vascepa distribution deal)
- HLS Therapeutics licensing arrangements generating $26.1M per 6 months
- Gross margin improved to 62.2% (vs. 38.6% prior year)
- Operating loss improved 67.7% despite restructuring charges
- Total H2 2025 Revenue: $145.4M vs. $84.7M (+71.6%)
⚠️ Critical Context:
- Licensing revenue includes ONE-TIME upfront payments + running royalties (not fully recurring)
- Product revenue (Vascepa) still only $93.2M H2 2025 (organic growth +11%)
- Restructuring charges ($18.8M H2 2025) reflect ongoing cost reduction
- Without licensing revenue: operating loss would be ~$35M (not -$16.2M)
5.3 Balance Sheet (Sept 30, 2025)
| Item | Sept 30, 2025 ($M) | Dec 31, 2024 ($M) |
|---|---|---|
| Cash & Equivalents | 122.8 | 121.0 |
| Short-term Investments | 163.8 | 173.2 |
| Total Liquidity | 286.6 | 294.2 |
| Total Assets | 659.8 | 685.3 |
| Total Liabilities | 200.9 | 199.2 |
| Stockholders' Equity | 458.9 | 486.2 |
| Shares Outstanding | ~415M | ~410M |
| Long-term Debt | — | — |
6. Generic Competition Timeline (VERIFIED)
⚠️ CRITICAL: Generic launches occurred EARLIER than many reports state
March 2020: First Patent Loss
Hikma Pharmaceuticals won patent litigation against Amarin (District Court decision, March 2020). This was the first major patent defeat.
November 2020: First Generic Launch
Hikma launched generic icosapent ethyl in November 2020, less than a month after patent litigation victory. This was the first competitive threat to Vascepa's market dominance.
Q1-Q2 2021: Multiple Generics Enter
By Q2 2021, at least 3-4 generic icosapent ethyl products were on the market or launching. Market share for Amarin dropped from ~95% to ~50-60% in icosapent ethyl market.
2022-2023: Continued Competition
Additional generics continued launching throughout 2022-2023. By mid-2022, Teva launched (after resolving API supply chain litigation), further fragmenting market.
2024-2025: Market Stabilization at New Equilibrium
By 2024-2025, generic icosapent ethyl captured dominant market share. Vascepa now competes as premium brand vs. cheaper generics. Amarin shifted strategy to international markets and cost reduction.
7. Market Position Today (November 2025)
7.1 Key Financial Metrics (H2 2025 - SEC Verified)
? Liquidity
$286.6M
Cash + Investments (Strong)
? H2 2025 Revenue
$145.4M
+71.6% YoY (Licensing Boom)
? Operating Loss
-$16.2M
H2 2025 (-67.7% improving)
? Organic Growth
+11.2%
Product Revenue YoY
7.2 SWOT Analysis
| STRENGTHS | WEAKNESSES | ||
|---|---|---|---|
|
|
✅ Positive Developments (H2 2025) — Strategic Pivot
- ? Licensing Revenue Explosion: $52.2M H2 2025 vs. $0.9M prior year
- Recordati Deal: European distribution partnership generating substantial upfront + running royalties
- HLS Therapeutics Arrangement: $26.1M per 6-month period from licensing/royalty stream
- Product Revenue Growth: +11.2% organic growth in core Vascepa sales (steady amid generics)
- Operating Loss Improvement: -67.7% YoY despite restructuring charges
- Gross Margin Expansion: 62.2% (vs. 38.6% prior year) from high-margin licensing revenue
- SG&A cut 46.6% post-restructuring (lean operations working)
? Critical Risk: Licensing Revenue Sustainability
- ONE-TIME vs. RECURRING: Much of $52.2M licensing includes upfront fees (not recurring)
- Product Sales Still Weak: Core Vascepa revenue only +11% (generic competition remains)
- Underlying Burn: Without licensing, operating loss would be ~$35M H2 2025
- Recordati Dependency: European distribution deal is crucial; any changes could impact revenue
- Pipeline Gap: No near-term pipeline catalysts beyond Vascepa licensing
- Market Share Erosion: Generic icosapent ethyl still dominant in US market
8. Official Sources & References
? SEC EDGAR Filings
- → SEC EDGAR: All 10-Q Filings
Quarterly financial results including H2 2025 (Sept 30, 2025) - → SEC EDGAR: All 10-K Annual Filings
Annual financial statements (FY 2024, 2021, 2020, etc.) - → NASDAQ AMRN SEC Filings
Complete filing directory | CIK: 0000897448 - → Amarin Investor Relations
Official financial documents and statutory accounts
? Official Press Releases
- → FDA Vascepa CV Approval (Dec 13, 2019)
Globe Newswire | Cardiovascular indication approval announcement - → REDUCE-IT Results (Nov 10, 2018)
AHA Conference presentation | 25% MACE reduction - → FDA Approval Analysis
Comprehensive analysis of cardiovascular indication approval
? Clinical Trial & Publications
- → REDUCE-IT Trial (NCT01492361)
ClinicalTrials.gov | Official study protocol and results - REDUCE-IT Trial: New England Journal of Medicine, November 2018
Bhatt DL, Steg PG, Miller M, et al. | 8,179 patients; 5-year follow-up; 25% MACE reduction - → REDUCE-IT Subanalysis (2024)
Lipoprotein(a) subgroup data | HLS Therapeutics
⚖️ Legal & Regulatory
- Hikma v. Amarin Patent Litigation
March 2020 District Court decision | First generic entry authorized - → Amarin Stock Information
Current stock data, historical prices, investor updates
⚠️ DISCLAIMER: This analysis is compiled from publicly available SEC filings, press releases, and clinical publications. It is NOT investment advice and does NOT constitute a recommendation to buy, sell, or hold Amarin stock. Biotech and pharmaceutical investments carry substantial risks including regulatory, clinical, competitive, and market risks. Past performance—whether 2021's peak or 2022's collapse—does not predict future results. Always conduct independent due diligence and consult qualified financial and legal advisors before making any investment decision.
Scanner for active traders
Try ChartsWatcher free, then unlock 10% OFF with SAVE10
ChartsWatcher is a real-time scanner for momentum traders: fast movers, unusual volume and rotations — so you can focus on the few tickers that matter right now, instead of watching hundreds of charts.
Start with the free version. When you upgrade, use SAVE10 for 10% OFF your first paid period.
Start free – then use SAVE10
No credit card required to start. Apply SAVE10 when upgrading.
Recommended platform
One platform. All your brokers.
Medved Trader connects multiple brokers in one workspace, with pro charts, hotkeys and fast execution — without changing your broker accounts.
A single cockpit for positions, Level II and multi-broker order routing, built for active day & swing traders.
Get 1 Month Free ➔
Multi-broker workflow + customizable layouts in one platform.
Monica.im – the AI assistant I use every day
If you find value in the work I publish on Merlintrader and want a practical AI assistant for research and writing, you can sign up using this referral link. Click here to try Monica.im and support the site
Find out how I use AI on Merlintrader: AI, retail and Merlintrader
Disclosure: some of the links in the promotional blocks above are affiliate or referral links. If you choose to subscribe or sign up through them, Merlintrader may receive a small commission or benefit at no extra cost to you.
